Frequency and clinical characteristics of hydroxychloroquine retinopathy in korean patients with rheumatologic diseases

Journal of Korean Medical Science

Volumn 32, Issue 3, 2017, Pages 522-527

  Eo, Doo Ri ^a   Lee, Min Gyu ^a   Ham, Don Il ^a   Kang, Se Woong ^a   Lee, Jaejoon ^a   Cha, Hoon Suk ^a   Koh, Eunmi ^a   Kim, Sang Jin ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Hydroxychloroquine; Hydroxychloroquine Retinopathy; Screening

Indexed keywords

ANTIRHEUMATIC AGENT; HYDROXYCHLOROQUINE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; DOSE CALCULATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; MIDDLE AGED; ODDS RATIO; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; RETINA; RETINAL DISEASES; RETROSPECTIVE STUDY; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX; SOUTH KOREA;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG DOSAGE CALCULATIONS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; ODDS RATIO; REPUBLIC OF KOREA; RETINA; RETINAL DISEASES; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL FIELD TESTS;

EID: 85013921332     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2017.32.3.522     Document Type: Article

References (27)

1. Dörner T. Therapy: hydroxychloroquine in SLE: old drug, new perspectives. Nat Rev Rheumatol 2010; 6: 10-1.
2. Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology (Oxford) 2008; 47: 378-9.
3. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 775-84.
4. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997; 40: 1482-6.
5. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003; 110: 1321-6.
6. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109: 1377-82.
7. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118: 415-22.
8. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016; 123: 1386-94.
9. Browning DJ, Lee C. Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clin Ophthalmol 2014; 8: 1389-99.
10. Asensio-Sánchez VM. SD-OCT As screening test for hydroxychloroquine retinopathy: the flying saucer sign. Arch Soc Esp Oftalmol 2015; 90: 338-40.
11. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014; 132: 1453-60.
12. Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 2015; 122: 110-6.
13. Elder M, Rahman AM, McLay J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol 2006; 124: 1729-33.
14. Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol 2011; 129: 30-9.
15. Bergholz R, Schroeter J, Rüther K. Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. Br J Ophthalmol 2010; 94: 1637-42.
16. Lai TY, Ngai JW, Chan WM, Lam DS. Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. Doc Ophthalmol 2006; 112: 177-87.
17. Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 2012; 130: 461-9.
18. Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, Yoo B, Koo BS, Kim JT, Marmor MF, et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology 2015; 122: 1252-6.
19. Cambiaggi A. Unusual ocular lesions in a case of systemic lupus erythematosus. AMA Arch Opthalmol 1957; 57: 451-3.
20. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985; 12: 692-4.
21. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006; 12: 294-304.
22. Silman A, Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol 1997; 36: 599-601.
23. Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 2008; 23: 201-9.
24. Hickley NM, Al-Maskari A, McKibbin M. Chloroquine and hydroxychloroquine toxicity. Arch Ophthalmol 2011; 129: 1506-7.
25. Mills PV, Beck M, Power BJ. Assessment of the retinal toxicity of hydroxychloroquine. Trans Ophthalmol Soc U K 1981; 101: 109-13.
26. Farrell DF. Retinal toxicity to antimalarial drugs: chloroquine and hydroxychloroquine: a neurophysiologic study. Clin Ophthalmol 2012; 6: 377-83.
27. Moschos MN, Moschos MM, Apostolopoulos M, Mallias JA, Bouros C, Theodossiadis GP. Assessing hydroxychloroquine toxicity by the multifocal ERG. Doc Ophthalmol 2004; 108: 47-53.